兽用头孢菌素类抗生素研究进展

doi:10.16431/j.cnki.1671-7236.2018.07.032

摘要/Abstract

摘要：

头孢菌素类抗生素具有抗菌谱广、抗菌活性强等特点，在人类医学领域应用十分广泛。在兽医临床中，由于药物种类较少及不规范使用而易使细菌产生交叉耐药性，头孢菌素的应用受到一定程度的限制。文章围绕兽用头孢菌素的发展历程、作用机制、药物代谢动力学与安全性等方面，总结了畜禽专用头孢菌素主要种类、抗菌活性及其在动物体内的药动学参数，比较了兽用头孢菌素的抗菌活性，以及其对敏感菌感染疾病的治疗效果。同时概述了头孢菌素类抗生素耐药性产生机制与耐药现状，并分析比较了各国在此类药物耐药性控制中采取的举措。通过对兽用头孢菌素类抗生素的发展及临床应用进行综述，有利于促进头孢菌素在兽医临床中的科学规范使用。

关键词: 兽用头孢菌素; 药效学; 药物代谢动力学; 不良反应; 耐药性

Abstract:

Cephalosporins are known for their broad spectrum and strong antibacterial activity in clinic.Cephalosporins are widely used in the medical field, but their application is partly restricted in veterinary medicine because of fewer classes,and cross resistance derived from abusing and misusing.Therefore,the review concluded the development process of cephalosporin, antibacterial mechanism, pharmacokinetics and safety, summarized the main classes of veterinary cephalosporin, antibacterial activity and pharmacokinetic parameters in animals, compared the antibacterial activity of the main veterinary cephalosporin and the therapeutic effect on sensitive bacterial infection diseases.Meanwhile,the resistance mechanism and the situation of resistance of cephalosporin were summarized, and the measures taken by various countries on the resistance control were compared and analyzed.Through the review of the development and clinical application of veterinary cephalosporin,it was made for promoting the scientific and standardized use of cephalosporin in benefit clinic.

Key words: veterinary cephalosporin; pharmacodynamics; pharmacokinetics; adverse effect; resistance

中图分类号:

S859.79⁺6

李梅, 孙灵灵, 袁宗辉, 黄玲利. 兽用头孢菌素类抗生素研究进展[J]. 《中国畜牧兽医》, 2018, 45(7): 1978-1989.

LI Mei, SUN Lingling, YUAN Zonghui, HUANG Lingli. Research Progress on Veterinary Cephalosporins[J]. , 2018, 45(7): 1978-1989.

参考文献

[1] 任妙贤,陈良柱,潘志坤,等.头孢维星研究概况[J].动物医学进展,2015,36(2):106-110. REN M X,CHEN L Z,PAN Z K,et al.Research progress on cefovecin[J].Progress in Veterinary Medicine, 2015,36(2):106-110.(in Chinese)
[2] 李洁云,顾觉奋.5代头孢菌素类抗生素的研究进展和市场动态[J].药学进展,2014,38(8):741-746. LI J Y,GU J F.Research progress and market trend of the fifth generation cephalosporin antibiotics[J].Progress in Pharmaceutical Sciences,2014,38(8):741-746.(in Chinese)
[3] CAPRILE K A.The cephalosporin antimicrobial agents:A comprehensive review[J].Journal Veterinary Pharmacology and Therapeutics,1988,11(1):1-32.
[4] WORTHINGTON R J,MELANDER C.Overcoming resistance to β-lactam antibiotics[J].Journal of Organic Chemistry,2013,78(9):4207-4213.
[5] BRADLEY A J,BREEN J E,PAYNE B,et al.The use of a cephalonium containing dry cow therapy and an internal teat sealant,both alone and in combina-tion[J].Journal of Dairy Science,2010,93(4):1566-1577.
[6] VASQUEZ A K,NYDAM D V,CAPEL M B,et al.Randomized noninferiority trial comparing 2 commercial intramammary antibiotics for the treatment of nonsevere clinical mastitis in dairy cows[J].Journal of Dairy Science,2016,99(10):8267-8281.
[7] PALAMARA J D,BONCZYNSKI J J,BERG J M,et al.Perioperative cefovecin to reduce the incidence of urinary tract infection in dogs undergoing hemilaminectomy[J].The Journal of the American Animal Hospital Association,2016,52(5):297-304.
[8] PAPICH M G, DAVIS J L,FLOERCHINGER A M.Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs[J].American Journal of Veterinary Research,2010,71(12):1484-1491.
[9] SONG I B,KIM T W,LEE H G,et al.Influence of the injection site on the pharmacokinetics of cefquinome following intramuscular injection in piglets[J].The Japanese Society of Veterinary Science,2013, 75(1):89-92.
[10] SWINKELS J M,COX P,SCHUKKEN Y H, et al.Efficacy of extended cefquinome treatment of clinical Staphylococcus aureus mastitis[J].Journal of Dairy Science,2013,96(8):4983-4992.
[11] MONTESISSA C,VILLA R,ANFOSSI P,et al.Pharmacodynamics and pharmacokinetics of cefoperazone and cefamandole in dogs following single dose intravenous and intramuscular administration[J].The Veterinary Journal,2003,166(2):170-176.
[12] STEVEN W, EBERHARD R.Cephalothin and cefazolin in vitro antibacterial activity and pharmacokinetics in dogs[J].Veterinary Surgery, 1995, 24:347-351.
[13] NIE H, FEN G, PENG J, et al.Comparative pharmacokinetics of ceftiofur hydrochloride and ceftiofur sodium after administration to water buffalo (Bubalus bubalis)[J].American Journal of Veterinary Research,2016,77(6):646-652.
[14] WENTE N,ZOCHE G V,BEHR M,et al.Susceptibility to cephalosporins of bacteria causing intramammary infections in dairy cows with a high somatic cell count in Germany[J].Preventive Veterinary Medicine, 2016,131:146-151.
[15] CARLI S,ANFOSSI P,VILLA R,et al.Absorption kinetics and bioavailability of cephalexin in the dog after oral and intramuscular administration[J].Journal of Veterinary Pharmacology and Therapeutics, 1999,22(5):308-313.
[16] COURTIN F,CRAIGMILL L,WETZLICH S E,et al.Pharmacokinetics of ceftiofur and metabolites after single intravenous and intramuscular administration and multiple intramuscular administrations of ceftiofur sodium to dairy goats[J].Journal of Veterinary Pharmacology and Therapeutics,1997,20(5):368-373.
[17] THOMAS E,THOMAS V,WILHELM C.Antibacterial activity of cefquinome against equine bacterial pathogens[J].Veterinary Microbiology,2006,115(1-3):140-147.
[18] CHRIST W.Pharmacological properties of cephalosporins[J].Infection,1991,19(S5):224-252.
[19] AMBROS L,KREIL V,TARRAGONA L,et al.Comparative pharmacokinetics of intravenous cephalexin in pregnant,lactating,and non-pregnant,non-lactating goats[J].Journal of Veterinary Pharmacology and Therapeutics,2011,34(4):397-402.
[20] ALBARELLOS G A,MONTOYA L,PASSINI S M,et al.Cefazolin pharmacokinetics in cats under surgical conditions[J].Journal of Feline Medicine and Surgery,2017,19(10):992-997.
[21] ALBARELLOS G A,MONTOYA L,LORENZINI P M,et al.Pharmacokinetics of cefuroxime after intravenous, intramuscular,and subcutaneous administration to dogs[J].Journal of Veterinary Pharmacology and Therapeutics,2016,39(1):40-44.
[22] WARAICH G S,SIDHU P K, DAUNDKAR P S,et al.Pharmacokinetic and pharmacodynamic characterization of ceftiofur crystalline-free acid following subcutaneous administration in domestic goats[J].Journal of Veterinary Pharmacology and Therapeutics,2017,40(5):429-438.
[23] TAHA A,ASHRAF E,MOHAMED E,et al.Comparative pharmacokinetics of cefoperazone following intravenous and intramuscular administration in goats[J].International Journal of Veterinary Science and Medicine,2015,3:21-25.
[24] COX S,SOMMARDAHL C,SEDDIGHI R,et al.Pharmacokinetics of intravenous and subcutaneous cefovecin in alpacas[J].Journal of Veterinary Pharmacology and Therapeutics,2015,38(4):344-349.
[25] UNEY K,ALTAN F,EROL H,et al.Plasma and synovial fluid pharmacokinetics of cefquinome following the administration of multiple doses in horses[J].Journal of Veterinary Pharmacology and Therapeutics,2017,40(3):239-247.
[26] SHAN Q,ZHU X,LIU S,et al.Pharmacokinetics of cefquinome in tilapia (Oreochromis niloticus) after a single intramuscular or intraperitoneal administra-tion[J].Journal of Veterinary Pharmacology and Therapeutics,2015,38(6):601-605.
[27] WILBER R B,DOYLE C A,DURHAM S J,et al.Safety profile of cefprozil[J].Clinical Infectious Diseases, 1992,14(S2):264-271.
[28] SCATTLER F R,WEITEKAMP M R,BALLARD J O.Potential for bleeding with the new β-lactam antibiotics[J].Annals of Internal Medicine,1986,105(6):924-931.
[29] JAMES J L,JOHN C L,WILLIAM J.Production of hypoprothrombinemia by moxalactam and 1-methyl-5-thiotetrazole in rats[J].Antimicrobial Agents and Chemotherapy,1984,25(3):380-381.
[30] STEELE R W, BRADSHER R W.Comparison of ceftriaxone with standard therapy for bacterial meningitis[J].The Journal of Pediatrics,1983,103(1):138-141.
[31] COHEN M S,WASHTON H E,BARRANCO S F.Multicentre clinical trial of cefoperazone sodium in the United States[J].The American Journal of Medicine,1985,79(1):35-41.
[32] VIAL T,PONT J,PHAM E,et al.Cefaclor-associated serum sickness-like disease:Eight cases and review of the literature[J].Annals of Pharmacotherapy,1992,26(7-8):910-914.
[33] NEU H C.Third generation cephalosporins:Safety profiles after 10 years of clinical use[J].Journal of Clinical Pharmacology,1990,30(5):396-403.
[34] HOWARD S J,CATCHPOLE M,WATSON J,et al.Antibiotic resistance:Global response needed[J].The Lancet Infectious Disease,2013,13(12):1001-1003.
[35] RICHMOND M H.Factors influencing the antibacterial action of β-lactam antibiotics[J].Journal of Antimicrobial Chemotherapy,1978,4:1-14.
[36] HARTMAN B,TOMASZ A.Altered penicillin-binding proteins in methicillin-resistant strains of Staphylococcus aureus[J].Antimicrobial Agents and Chemotherapy,1981,19(5):726-735.
[37] JACKSON G G,LOLANS V T,GALLEGOS B G.Comparative activity of bacterial β-lactamases on penicillins and cephalosporins[J].The Journal of Infectious Diseases,1973,128:327-334.
[38] GIRLICH D,POIREL L CARATTOLI A,et al.Extended-spectrum β-lactamase CTX-M-1 in Escherichia coli isolates from healthy poultry in France[J].Applied and Environmental Microbiology,2007,73(14):4681-4685.
[39] JØRGENSEN C J,CAVACO L M,HASMAN H,et al.Occurrence of CTX-M-1-producing Escherichia coli in pigs treated with ceftiofur[J].Journal Antimicrobial Chemotherapy,2007,59(5):1040-1042.
[40] ARLET G,BARRETT T J,BUTAYE P,et al.Salmonella resistant to extended-spectrum cephalosporins:Prevalence and epidemiology[J].Microbes and Infection,2006,8(7):1945-1954.
[41] RIAÑO I,MORENO M A,TESHAGER T,et al.Detection and characterization of extended-spectrum β-lactamases in Salmonella enterica strains of healthy food animals in Spain[J].Journal of Antimicrobial Chemotherapy,2006,58(4):844-847.
[42] BRIÑAS L,MORENO M A,TESHAGER T,et al.Monitoring and characterization of extended-spectrum β-lactamases in Escherichia coli strains from healthy and sick animals in Spain in 2003[J].Antimicrobial Agents and Chemotherapy,2005,49(3):1262-1264.
[43] KOECK J L,ARLET G,PHILIPPON A,et al.A plasmid-mediated CMY-2β-lactamase from an Algerian clinical isolate of Salmonella senftenberg[J].FEMS Microbiology Letter,1997,152(2):255-260.
[44] ALCAINE S D,SUKHNANAND S S,WARNICK L D,et al.Ceftiofur-resistant Salmonella strains isolated from dairy farms represent multiple widely distributed subtypes that evolved by independent horizontal gene transfer[J].Antimicrobial Agents and Chemotherapy,2005,49(10):4061-4067.
[45] SMET A,MARTEL A,PERSOONS D,et al.Diversity of extended-spectrum β-lactamases and class C β-lactamases among cloacal Escherichia coli isolates in Belgian broiler farms[J].Antimicrobial Agents and Chemotherapy,2008,52(4):1238-1243.
[46] BOIREAU C,CAZEAU G,JARRIGE N,et al.Antimicrobial resistance trends in Escherichia coli isolated from diseased food-producing animals in France:A 14-year period time-series study[J].Zoonoses and Public Health,2017,65(1):86-94.
[47] TESHAGER T,DOMINGUEZ L,MORENO M A, et al.Isolation of an SHV-12β-lactamase-producing Escherichia coli strain from a dog with recurrent urinary tract infections[J].Antimicrobial Agents and Chemotherapy,2000,44(12):3483-3484.
[48] SHIRAKI Y,SHIBATA N,DOI Y,et al.Escherichia coli producing CTX-M-2β-lactamase in cattle,Japan[J].Emerging Infectious Diseases,2004,10(1):69-75.
[49] WEILL F X,LAILLER R,PRAUD K,et al.Emergence of extended-spectrum β-lactamase (CTX-M-9) -producing multiresistant strains of Salmonella enterica serotype virchow in poultry and humans in France[J].Journal of Clinical Microbiology,2004,42(12):5767-5773.
[50] POLITI L,TASSIOS T T,LAMBIRI M,et al.Repeated occurrence of diverse extended-spectrum β-lactamases in minor serotypes of food-borne Salmonella enterica subsp.Enterica[J].Journal Clinical Microbiology,2005,43(7):3453-3456.
[51] BERTRAND S,WEILL F X,VRINTS M,et al.Clonal emergence of extended-spectrum β-lactamase (CTX-M-2)-producing Salmonella enterica serovar virchow isolates with reduced susceptibilities to ciprofloxacin among poultry and humans in Belgium and France (2000 to 2003)[J].Journal of Clinical Microbiology,2006,44(8):2897-2903.
[52] HASMAN H,MEVIUS D,VELDMAN K,et al.β-lactamases among extended-spectrum β-lactamase (ESBL)-resistant Salmonella from poultry,poultry products and human patients in The Netherlands[J].Journal of Antimicrobial Chemotherapy,2005,56(1):115-121.
[53] CHEN S, ZHAO S H, WHITE D G,et al.Characterization of multiple-antimicrobial-resistant Salmonella serovars isolated from retail meats[J].Applied and Environmental Microbiology,2004,70(1):1-7.
[54] ARESTRUP F M,HASMAN H,OLSEN I,et al.International spread of bla_CMY-2-mediated cephalosporin resistance in a multiresistant Salmonella enterica serovar heidelberg isolate stemming from the importation of a boar by denmark from Canada[J].Antimicrobial Agents and Chemotherapy,2004,48(5):1916-1917.
[55] BRADFORD P A,PETERSEN P J,FINGERMAN I M,et al.Characterization of expanded-spectrum cephalosporin resistance in E.coli isolates associated with bovine calf diarrhoeal disease[J].Journal of Antimicrobial Chemotherapy,1999,44(5):607-610.
[56] KOJIMA A,ISHⅡ Y,ISHIHARA K,et al.Extended-spectrum-β-lactamase-producing Escherichia coli strains isolated from farm animal from 1999 to 2002:Report from the Japanese veterinary antimicrobial resistance monitoring program[J].Antimicrobial Agents and Chemotherapy,2005,49(8):3533-3537.
[57] VO A T,DUIJKEREN E V,FLUIT A C,et al.Characteristics of extended-spectrum cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolates from horses[J].Veterinary Microbiology,2007, 124(3-4):248-255.
[58] EARNSHAW S,MENDEZ A,MONNET D L,et al.Global collaboration to encourage prudent antibiotic use[J].The Lancet Infectious Disease,2013,13(12):1003-1004.
[59] VOELKER R.FDA:Limited ban on cephalosporin use in major food-producing animals[J].Journal of the American Association,2012,307(5):443.
[60] AGERSOØ Y,AARESTRUP F M.Voluntary ban on cephalosporin use in Danish pig production has effectively reduced extended-spectrum cephalosporinase-producing Escherichia coli in slaughter pigs[J].Journal of Antimicrobial Chemotherapy,2013,68(3):569-572.
[61] DUTIL L,IRWIN R,FINLEY R,et al.Ceftiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans,Canada[J].Emerging Infectious Diseases,2010,16(1):48-54.
[62] 刘玉华,王琳琳,方向红,等.鸡源大肠杆菌超广谱β-内酰胺酶的检测及耐药性分析[J].中国畜牧兽医,2014,41(12):271-275. LIU Y H,WANG L L,FANG X H,et al.Detection and analysis of drug resistance of ESBLs in Escherichia coli strains isolated from chickens[J].China Animal Husbandry & Veterinary Medicine,2014,41(12):271-275.(in Chinese)
[63] 薛雨,陈宇瑛.头孢菌素类抗生素的最新研究进展[J].中国抗生素杂志,2011,36(2):86-92. XUE Y,CHEN Y Y.New development of cephalosporin antibiotics[J].Chinese Journal of Antibiotics,2011,36(2):86-92.(in Chinese)